Related Experiment Videos

Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated

Christophe Meune1, Isabelle Mahé, Jean-Jacques Mourad

  • 1Internal Medicine, Hospital Lariboisière, Paris, France. christophe.meune@cch.ap-hop-paris.fr

European Journal of Heart Failure
|June 12, 2003
PubMed

Insights

Aspirin negatively impacts arterial function in chronic heart failure (CHF) patients on ACE inhibitors, with higher doses causing more significant adverse effects on arterial properties.

Area of Science:

  • Cardiovascular Pharmacology
  • Vascular Physiology

Background:

  • Aspirin's inhibition of prostaglandin synthesis may adversely affect arterial function and ACE inhibitor efficacy in chronic heart failure (CHF).
  • Understanding aspirin's impact on arterial properties in CHF patients receiving ACE inhibitors is crucial.

Purpose of the Study:

  • To prospectively assess the effects of aspirin on arterial functional properties in CHF patients treated with ACE inhibitors.

Main Methods:

  • Prospective, single-blind study involving 18 CHF patients over three 7-day periods: placebo, aspirin 100 mg/day, and aspirin 325 mg/day.
  • Evaluated reflected wave analysis, pulse wave velocity, blood pressure, thromboxane B2 (TxB2), and prostaglandins.
  • Radial applanation tonometry was used for arterial assessment.

Main Results:

  • Aspirin 325 mg/day significantly increased augmentation index and decreased reflected wave traveling times.
  • Aspirin 100 mg/day showed a similar, non-significant trend.
  • Both aspirin doses significantly reduced serum TxB2, but did not affect prostaglandin I2 metabolites.

Conclusions:

  • Aspirin exerts a dose-dependent, detrimental effect on arterial functional properties in CHF patients treated with ACE inhibitors.
  • This highlights potential risks associated with aspirin use in this patient population.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...